Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint

COMPASS Pathways plc

2025-Q2 EPS reported -$0.62 vs consensus -$0.44 ▼ miss (-42.0%)

Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.
Second pivotal Phase 3 (COMP006) enrolling well; 26-week data expected H2 2026.
Exploring accelerated filing pathway for COMP360 in TRD; DSMB found no safety concerns in Phase 3 studies.
Net loss $38.4M (Q2 2025) vs $38.1M (Q2 2024); net loss per share $0.41 vs $0.56.
Cash $221.9M at June 30, 2025; cash runway into 2027; FY2025 net cash used in ops guidance $120-145M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.